Illinois General Assembly - Bill Status for SB1454

Replaces everything after the enacting clause. Amends the Illinois Controlled Substances Act. Defines Prescription Monitoring Program Advisory Committee. Includes as a Schedule II controlled substance Dihydrocodeinone (Hydrocodone), with one or more active, non-narcotic ingredients in regional therapeutic amounts. Provides that as of January 1, 2015 each Schedule II prescription must be issued via electronic prescribing. All electronic prescribing must pass through the Prescription Monitoring Program portal, to establish an audit trail regarding the eventual dispensing of the medication. Provides that upon review by the Prescription Monitoring Program Advisory Committee of prescribers who have not registered as Prescription Monitoring Program users, the Committee by means of an intergovernmental agreement shall generate a file of information regarding these practitioners with consistently high numbers of patients with multiple prescribers which shall be submitted to the Department of Financial and Professional Regulation. Provides that by January 1, 2015, all Electronic Health Records Systems must interface with the Prescription Monitoring Program application program interface to insure that all providers have access to specific patient records as they are treating the patient. Provides that the Prescription Monitoring Program Advisory Committee shall report to the Director of the Division of Alcoholism and Substance abuse, the Director of Public Health, and the Secretary of the Department of Financial and Professional Regulation annually, their trended evaluation of the historic prescribing of controlled substances. Provides that as part of this report they shall make recommendations for courses of continuing professional education and other training materials for licensed health care professionals in the appropriate use of pain medications. Provides that the Prescription Monitoring Program Advisory Committee shall provide outreach and assistance to health care professional organizations to encourage and facilitate continuing medical education training programs for their members regarding appropriate prescribing practices for optimum patient care.

Replaces everything after the enacting clause. Amends the Wholesale Drug Distribution Licensing Act. Provides that notwithstanding any other provision of law, a distributor licensed and regulated by the Department of Financial and Professional Regulation, and registered and regulated by the United States Drug Enforcement Administration, shall be exempt from the storage, reporting, ordering, record keeping and physical security control requirements for Schedule II controlled substances with regard to any material, compound, mixture or preparation containing Hydrocodone. These Controlled Substances shall be subject to the same requirements as those imposed for Schedule III controlled substances. Amends the Illinois Controlled Substances Act. Defines Prescription Monitoring Program Advisory Committee and electronic health record. Includes as a Schedule II controlled substance Dihydrocodeinone (Hydrocodone), with one or more active, non-narcotic ingredients in regional therapeutic amounts. Provides that by January 1, 2015, all Electronic Health Records Systems should interface with the Prescription Monitoring Program application program interface to insure that all providers have access to specific patient records as they are treating the patient. Makes other changes.

Replaces everything after the enacting clause. Amends the Wholesale Drug Distribution Licensing Act. Provides that notwithstanding any other provision of law, a distributor licensed and regulated by the Department of Financial and Professional Regulation, and registered and regulated by the United States Drug Enforcement Administration, shall be exempt from the storage, reporting, ordering, record keeping and physical security control requirements for Schedule II controlled substances with regard to any material, compound, mixture or preparation containing Hydrocodone. These Controlled Substances shall be subject to the same requirements as those imposed for Schedule III controlled substances. Amends the Illinois Controlled Substances Act. Defines Prescription Monitoring Program Advisory Committee and electronic health record. Provides that Dihydrocodeinone (Hydrocodone) with one or more active, non-narcotic ingredients in regional therapeutic amounts is a Schedule III controlled substance, subject to the requirements for prescribing of Schedule III controlled substances with the exception that any prescription must be limited to no more than a 30-day supply with any continuation requiring a new prescription. Provides that prescribers may issue multiple prescriptions (3 sequential 30-day supplies) for Dihydrocodeinone (Hydrocodone), authorizing up to a 90-day supply. Provides that by January 1, 2018, all Electronic Health Records Systems should interface with the Prescription Monitoring Program application program interface to insure that all providers have access to specific patient records as they are treating the patient. Makes other changes.

×